Taiwan looking to jump-start biotech through new fund
This article was originally published in Scrip
Taiwan has launched a major new public-private venture capital fund dedicated to the biotechnology sector, through which it is looking to raise at least NT$5 billion ($172 million) by the end of the year.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.